糖尿病心血管疾病的非降脂治疗与临床评价ppt课件_第1页
糖尿病心血管疾病的非降脂治疗与临床评价ppt课件_第2页
糖尿病心血管疾病的非降脂治疗与临床评价ppt课件_第3页
糖尿病心血管疾病的非降脂治疗与临床评价ppt课件_第4页
糖尿病心血管疾病的非降脂治疗与临床评价ppt课件_第5页
已阅读5页,还剩30页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

Clinical Evaluation and Nonlipid Treatment of Coronary Artery Disease in the Diabetic Patient Richard Nesto, MD Prevalence of Asymptomatic CAD in Diabetes Mellitus Koistinen MJ. BMJ 1990;301:92-95. Type 2 Type 1 Controls Naka M et al. Am Heart J 1992;123:46-53. Type 2 Controls MiSAD Group. Am J Cardiol 1997;79:134-139. Type 2 Rutter MK et al. Am J Cardiol 1999;83:27-31. Type 2 w microalb Type 2 w/o microalb Le A et al. Am J Kidney Dis 1994;24:65-71. Type 1 Renal Transplant Holley JL et al. Am J Med 1991;90:563-570. Type 1 121:1268-1273. Blood Pressure and CVD: Framingham Heart Study Age-adjusted CV Event Rate/1,000 Systolic BP (mmHg) 105135165195 Systolic BP (mmHg) 105135165195 Age-adjusted CV Event Rate/1,000 24 50 38 77 59 119 90 174 15 31 23 48 36 74 56 113 No Glucose Intolerance Glucose Intolerance No Glucose Intolerance Glucose Intolerance MENMENWOMENWOMEN UKPDS Group. Lancet 1998;352:837-853. Effect of Glycemic Control in the UK Prospective Diabetes Study (UKPDS) Any diabetes related* MI Stroke PVD Microvascular 40.9 14.7 5.6 1.1 8.6 46 17.4 5 1.6 11.4 0.029 0.052 0.52 0.15 0.0099 11 16 25 (rate/1000 pt yrs) * Combined microvascular and macrovascular events Intensive % Decrease (rate/1000 pt yrs)P Conventional Endpoints Reasons for Death in UKPDS Intensive Treatment Arm: 10-Year Follow-up UKPDS Group. Lancet 1998;352:837-853. Fatal MI or SD Cancer Other Fatal Stroke Renal Disease Accidents PVD Hypo- or Hyperglycemia 231 120 74 43 16 5 2 1 (8.4%) (4.4%) (2.9%) (1.6%) (0.6%) (0.2%) (0.07%) (0.04%) (%) N = 2729 47%47% 8.7%8.7% 24%24% 15%15% 3.3%3.3% 2.5%2.5% MI or SDMI or SD CancerCancer StrokeStroke OtherOther RenalRenal Accidents, PVD, Hypo-Accidents, PVD, Hypo- 317:703-713. Effect of Blood Pressure Control in the UKPDS Tight vs. Less Tight Control Any diabetes-related endpoint Diabetes-related deaths Heart failure Stroke Myocardial infarction Microvascular disease Tight Control n 1,148 Type 2 patients n Average BP lowered to 144/82 mmHg (controls: 154/87); 9-year follow-up 24 32 56 44 21 37 Risk Reduction (%)P value 0.0046 0.019 0.0043 0.013 NS 0.0092 UKPDS: ACE Inhibitor vs. Beta-blocker for HTN Aggregate Clinical Endpoints 0.50.5 1 1 2 2 Relative Risk 317:713-720. FavorsFavors ACE inhibitorACE inhibitor FavorsFavors Beta blockerBeta blocker Placebo Events / 1000 Pt-Years Systolic Hypertension in Europe (Syst-Eur) Trial: Effect of Systolic BP Control on All Cardiovascular Events at 2 Years Tuomilehto J et al. NEJM 1999;340: 677-684. N=492; N=492; P P=0.002=0.002 Active Rx 57.657.6 22.022.0 62%62% RiskRisk ReductionReduction N=4,203; N=4,203; P P=0.02=0.02 31.431.4 23.523.5 PlaceboActive Rx 25%25% RiskRisk ReductionReduction Diabetic PatientsNondiabetic Patients Major CV EventsMI Events / 1000 Pt-Years Major Outcomes of the Hypertension Optimal Treatment (HOT) Trial: Diabetes Subgroup Hansson L et al. Lancet 1998;351: 1755-1762. CV Mortality 90 mmHg (N=501) 85 mmHg (N=501) 80 mmHg (N=499) Diastolic Target p0.045 p0.016 p0.005 90 Events / 1000 Pt-Years HOT Trial:Cardiovascular Events in Diabetics and NondiabeticsEffect of Diastolic Target at 4 Years Hansson L et al. Lancet 1998;351: 1755-1762. DiabeticDiabetic Patients Patients n=1,501; p=0.016n=1,501; p=0.016 8580908580 NondiabeticNondiabetic Patients Patients n=18,790; p=NSn=18,790; p=NS 24.424.4 18.618.6 11.911.9 9.99.9 10.010.0 9.39.3 48%48% RiskRisk ReductionReduction Completed Clinical Trials with Antihypertensive Agents in Diabetes SHEP = Systolic Hypertension in the Elderly Program; GISSI = Grupo Italiano per lo Studio della Sopravvivenza nellInfarto Miocardico; Syst-Eur = Systolic Hypertension in Europe; HOT = Hypertension Optimal Treatment; CAPPP = Captopril Prevention Project Curb JD et al. JAMA 1996;276:1886-1892; Zuanetti G et al. Circulation 1997;96:4239-4245; Staessen JA et al. Am J Cardiol 1998;82:20R-22R; Hansson L et al. Lancet 1998;351:1755-1762;UK Prospective Diabetes Study Group. BMJ 1998;317:703-713; Hansson L et al. Lancet 1999;353:611-616. SHEP GISSI-3 Syst-Eur HOT UKPDS CAPPP Results on CVDResults on CVDDiabetic/TotalDiabetic/TotalTrialTrial 583/4736 2790/18,131 492/4695 1501/18,790 1148 572/10,985 Beneficial Beneficial Beneficial Beneficial Beneficial Beneficial Heart Outcomes Prevention Evaluation (HOPE) Study Effect of Ramipril on Cardiovascular Events (Myocardial Infarction, Stroke, or CVD Death) 4.5 Yrs Hope Study Investigators. NEJM 2000;342:145-153. Placebo % of Patients Ramipril 19.819.8 15.015.0 24%24% RiskRisk ReductionReduction 16.416.4 13.013.0 PlaceboRamipril 21%21% RiskRisk ReductionReduction Diabetic PatientsNondiabetic Patients N=3,578, N=3,578, P P=0.001=0.001N=5,719, N=5,719, P P=0.001=0.001 Diabetes Increases Risk of Coronary Plaque Disruption and Thrombosis Cause of Myocardial Infarction PlaquePlaque FormationFormation F VIIF VII F VIIIF VIII Coronary ArteryCoronary Artery Sympathetic ToneSympathetic Tone PAI-1PAI-1 TPATPA PGIPGI 2 2 Platelet AggregationPlatelet Aggregation FibrinogenFibrinogen vWFvWF ThrombusThrombus PlaquePlaque DisruptionDisruption Impact of Serum Fibrinogen and Total Cholesterol Levels on Risk of Coronary Events in ECAT Thompson SG. N Engl J Med 1995;332:635-641. Fibrinogen Lower Middle Higher Higher Middle Lower Total Cholesterol Risk of Coronary Events (%) 4/306 9/261 10/2825/311 3/247 10/281 11/266 16/304 21/305 Effect of Aspirin on Mortality in Type 2 Patients with CHD: Bezafibrate Infarction Prevention Study Harpaz D et al. Am J Med 1998;105:494-499. Survival (%) No diabetes Type 2 diabetes Time (Years) 0123456 No aspirin Aspirin OR=0.8 (0.7-0.9) OR=0.7 (0.6-0.8) Antiplatelet Agents Reduce CVD Events in Patients with Diabetes: Antiplatelet Trialists Collaboration Antiplatelet Trialists Collaboration. BMJ 1994;308:81-106. CVD Events (%) Diabetes Antiplatelet Therapy Control No Diabetes P0.002 P0.00001 Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI): Benefit of Tight Glycemic Control in No Insulin Low Risk Cohort Malmberg K et al. BMJ 1997;314:1512-1515. 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 Mortality Mortality Total CohortNo Insulin Low Risk Years in StudyYears in Study Control Insulin-glucose Infusion 012345012345 Insulin-glucose Infusion Control p = .0111p = .004 n=133 n=139 n=314 n=306 Effect of Trandolapril on Post-MI CHF Progression: Trandolapril Cardiac Evaluation (TRACE) Years Gustafsson I et al. J Am Coll Cardiol 1999;34:83-89. Diabetics (n=237)Diabetics (n=237) 01234 Event Rate Years NondiabeticsNondiabetics (n=1512) (n=1512) 01234 Event Rate Relative risk, 0.38 P0.001 Relative risk, 0.81 P = 0.1 Placebo Trandolapril Placebo Trandolapril Cardiovascular death Sudden death Reinfarction Progression in CHF DiabeticsDiabetics RR (95% CI) RR (95% CI) P P End PointEnd Point Effect of Trandolapril on Secondary Endpoints in TRACE 0.56 (0.37-0.85) 0.46 (0.25-0.85) 0.55 (0.29-1.07) 0.38 (0.21-0.67) 0.79 (0.66-0.96) 0.84 (0.63-1.12) 0.93 (0.69-1.26) 0.81 (0.63-1.04) 0.17 0.09 0.15 0.03 NondiabeticsNondiabetics RR (95% CI) RR (95% CI) P P InteractionInteraction P P CI = confidence interval; RR = relative risk. Gustafsson I et al. J Am Coll Cardiol 1999;34:83-89. 0.01 0.01 0.08 0.001 0.02 0.23 0.65 0.10 Woodfield SL et al. J Am Coll Cardiol 1996;28:1661-1669. Effect of Diabetes on 30-Day Mortality: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) 2.7 2.1 2.4 2.0 012345 Odds Ratio for 30-Day Mortality Diabetes vs no diabetes (unadjusted) Adjusted for clinical variables Adjusted for angiographic variables Adjusted for clinical 342:989-997. 0 Mortality DM-PTCA DM-CABG Non DM-CABG Non DM-PTCA Follow-up (years) 0.25 0.18 0.08 0.07 12345 Impact of PTCA vs. CABG on Mortality in BARI-1 Mortality Follow-up (years)Years after Q-MI DM-PTCA DM-CABG Non DM-CABG Non DM-PTCA Mortality Mortality in PatientsMortality in Patients without Q-MIwithout Q-MI Mortality in PatientsMortality in Patients After Q-MIAfter Q-MI 012345012345 0.220.22 0.160.16 0.070.07 0.060.06 0.790.79 0.290.29 0.270.27 0.170.17 Detre KM et al. N Engl J Med 2000;342:989-997. Impact of Diabetes on 7-year Survival in BARI BARI Investigators. J Am Coll Cardiol 2000;35:1122-1129. % Survival 01345726 Years Patients without Treated DiabetesPatients without Treated Diabetes % Survival 01345726 All PatientsAll Patients % Survival 01345726 Patients with Treated DiabetesPatients with Treated Diabetes p = 0.0425 p = 0.7155p = 0.0011 CABG (n=914) PTCA (n=915) CABG (n=180) PTCA (n=173) CABG (n=734) PTCA (n=742) 84.4 80.9 76.4 55.7 86.8 86.4 Eight-Year Mortality in Emory Angioplasty vs Surgery Trial (EAST) King SB III et al. J Am Coll Cardiol 2000;35:1116-1121. % Survival Years after Randomization Patients without DiabetesPatients without Diabetes % Survival All EAST PatientsAll EAST Patients % Survival Treated Diabetic PatientsTreated Diabetic Patients p = 0.40 p = 0.71p = 0.23 CABG (n=194) PTCA (n=198) CABG (n=30) PTCA (n=29) CABG (n=164) PTCA (n=169) 013458276 013458276013458276 82.7 79.3 6-Month Angiographic Outcome after PTCA in Diabetes (377 Patients with 476 Lesions) Van Belle E et al. J Am Coll Cardiol 1999;34:476-485. Lesions (%) Angiographic FU = 6 months 62% PTCA Site(s) 1 Site2 Sites3 Sites OverallOverall Restenosis Restenosis Rate RateTotal OcclusionTotal Occlusion 49%49% 13%13% Restenosis (n = 237) Total Occlusion (n = 60) Patients (%) 11% 25% 37% Impact of Restenosis and Total Occlusion on LV Function in Diabetes Van Belle E et al. J Am Coll Cardiol 1999;34:476-485. in EF (%) p = nsp = nsp = 0.0001 (n = 297)(n = 237)(n = 60) Restenosis () Total Occlusion () Restenosis (+) Total Occlusion () Total Occlusion (+) -1.5+9.5 +0.5+9.9 -6.2+9.9 Effect of Stents on Target Vessel Revascularization (TVR) after PTCA in Diabetes 1.00 0.95 0.90 0.85 0.80 0.75 0.70 0 Proportion Free of TVR p = 0.021 df = 3, Log-rank Test Rankin JM et al. Circulation 1998;98:I-79. Months Post PTCA 024681012 Year 1994 1995 1996 1997 1997 1996 1995 1994 N 305 425 480 288 % Stent 17.4 24.9 41.0 55.5 Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT): Benefit of Abciximab and Stenting in Diabetes on Reducing TVR Lincoff AM et al. N Engl J Med 1999;341:319-327. Days after Randomization Stent + Placebo Stent + Abciximab Angioplasty + Abciximab Patients with DiabetesPatients with Diabetes (n = 491)(n = 491) 0309012018060150 Incidence of repeated TVR at 6 mos. (%) Days after Randomization Patients without DiabetesPatients without Diabetes (n = 1908)(n = 1908) 0309012018060150 Incidence of repeated TVR at 6 mos. (%) 18.4% 16.6% 8.1% 14.6% Stent + Placebo Stent + Abciximab Angioplasty + Abciximab 9.0% 8.8% % of Patients Days EPISTENT:

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论